中
Home
About TUL
Group Introduction
Executive Directors
Subsidiaries
Contact Us
Innovation in R&D
R&D Pipeline
R&D Platform
R&D Updates
News
TUL Highlights
Product Center
Finished Products
Comprehensive Health Products
APIs and Intermediates
Animal protection products
Empty capsule
Medical device
Cosmetic Peptide Series
Sustainability
Enhancing Governance
Normalizing Healthiness
Brand Building
People-Oriented
Green Development
ESG Reports
ESG News
Investor Relations
Innovation in R&D
R&D Pipeline
R&D Platform
R&D Updates
2026-09-08
UBT251 INJECTION COMPLETED FIRST PARTICIPANT DOSING IN PHASE III CLINICAL STUDY FOR TYPE 2 DIABETES IN CHINA
Learn More
2026-09-07
UBT251 INJECTION COMPLETED FIRST PARTICIPANT DOSING IN PHASE III CLINICAL STUDYFOR OVERWEIGHT OR OBESITY IN CHINA
Learn More
2026-08-12
FDA APPROVAL OF IND FOR THE GROUP’S PRODUCT UBT48128 TABLETS
Learn More
2026-07-15
APPROVAL FOR MARKETING OF THE GROUP’S PRODUCT SODIUM HYALURONATE EYE DROPS WITH NEW SPECIFICATION
Learn More
2026-07-03
APPROVAL FOR MARKETING OF THE GROUP’S PRODUCT TADALAFIL TABLETS
Learn More
All News
Select Year
2026
2025
2024
Triple agonist UBT251 delivers up to 19.7% mean weight loss after 24 weeks in phase 2 trial in China
2026-02-25
THE GROUP’S PRODUCT ROXITHROMYCIN CAPSULES PASSED THE CONSISTENCY EVALUATION
2026-02-10
APPROVAL FOR CLINICAL TRIAL OF UBT251 INJECTION ON INDICATION OF OSA
2026-02-04
FDA APPROVAL OF IND FOR GROUP’S PRODUCT TUL108 FOR INJECTION
2026-02-04
UPDATED INFORMATION ON THE GROUP’S PRODUCT MOXIFLOXACIN HYDROCHLORIDE EYE DROPS
2025-12-10
UPDATED INFORMATION ON THE GROUP’S PRODUCT LEVOFLOXACIN EYE DROPS
2025-12-10
THE GROUP’S PRODUCT CEFOPERAZONE SODIUM ANDSULBACTAM SODIUM FOR INJECTIONPASSED THE CONSISTENCY EVALUATION
2025-11-27
THE GROUP’S PRODUCT AMOXICILLIN SODIUMAND CLAVULANATE POTASSIUM FOR INJECTIONPASSED THE CONSISTENCY EVALUATION
2025-11-13
APPROVAL FOR CLINICAL TRIAL OF UBT37034 FOR INJECTIONON INDICATION OF OVERWEIGHT OR OBESITY
2025-11-13
FDA APPROVAL OF IND FOR UBT37034 INJECTION
2025-11-13
TUL's cefotaxime sodium for injection (specification: ①1.0g②2.0g, trademark name: 赛福隆®) was approved to pass the consistency evaluation of quality and efficacy.
2025-07-30
TUL’s Liraglutide Injection Approved for Market Launch
2025-03-21
Prev
1
2
3
4
Next
WeChat
Official
Account
To Top